The research and development of new stem cell drugs in China is advancing at a new speed. Nearly 103 clinical trial applications for stem cell drugs have been accepted, and many of these new stem cell drugs have entered the clinical research stage.‌

Kyoto University Hospital is studying a treatment for severe type 1 diabetes that uses induced pluripotent stem cells (iPS) to reprogram into islet cells to produce hormones that regulate blood sugar levels.

Mesenchymal stem cells (MSC) have high plasticity, self-renewal capabilities, immunosuppressive and anti-inflammatory properties, and have become a promising technology for the treatment of knee osteoarthritis (OA).

Many clinical studies have reported the safety and effectiveness of MSC therapy in promoting sports injuries.

In February 2023, she received a revolutionary stem cell therapy. Doctors transplanted labor-grown islet cells into her body, and within a few months, she no longer needed to rely on external insulin.

Induced Pluripotent Stem Cells: Some genes (originally Oct3/4, Soc2, c-Myc and Klf4) are introduced into ordinary body cells such as skin through a retroviral vector, and they are "initialized" to enable them to function as stem cells. These are "iPSCs".

CDE interprets the "Guidelines for Adaptive Design of Drug Clinical Trials (Trial Implementation)"

In August 2024, the Beijing City Semi-annual Working Conference on Drug Regulation was held, and it was particularly affirmed that the work of issuing the country's first stem cell "Drug Production License" was carried out.